Many patients with overweight or obesity discontinue glucagon-like peptide-1 (GLP-1) receptor agonist therapy within o ...
Liraglutide, a GLP-1 significantly lowers the rate of recurrent stroke in patients with diabetes, with no apparent increase ...
WVU Medicine is playing a lead role in a national clinical study of a minimally invasive surgical procedure for people who've ...
News Medical on MSN10d
High discontinuation rates of GLP-1 agonists found among patients with obesityDiscontinuation of GLP-1 receptor agonists in obesity is common, driven by weight regain and socioeconomic factors, impacting ...
A majority with overweight/obesity discontinue within a year, but the rate is higher among those without type 2 diabetes.
HealthDay News — The absolute risk for thyroid cancer is low among patients receiving glucagon-like peptide-1 receptor agonist (GLP-1 RA) therapy, but risk is elevated in the first year of treatment, ...
The GLP-1 receptor agonist exenatide failed to meet its primary outcome in a phase III trial of Parkinson's disease patients.
Greater weight loss was linked to lower discontinuation rates, with a 1% reduction in weight lowering the hazard of ...
A large cohort study examining more than 125,000 adults in the U.S. found that the majority of patients discontinue GLP-1 RA therapy within the first year, with those without Type 2 diabetes showing ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback